Bomedemstat — Investigational Agent
Other · Phase 3 · Merck (Imago BioSciences)
Mechanism of Action
Bomedemstat is an orally administered, irreversible inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A), a flavin-dependent enzyme that regulates the epigenetic transcriptional program governing hematopoietic stem and progenitor cell differentiation. In myeloproliferative neoplasms, LSD1 is required for the survival and self-renewal of malignant megakaryocyte and progenitor populations. Inhibition promotes differentiation and apoptosis of the neoplastic clone, reducing pathologic megakaryopoiesis and platelet overproduction. Preclinical and clinical data show reductions in mutant allele…
Investigational Indications
- Essential thrombocythemia
- Myelofibrosis
- Polycythemia vera